Newer Methods for Ventricular Tachycardia Ablation and When to Use Them

William G. Stevenson, John L. Sapp

Résultat de recherche: Review articleexamen par les pairs

9 Citations (Scopus)

Résumé

Radiofrequency (RF) catheter ablation has long been an important therapy for ventricular tachycardia and frequent symptomatic premature ventricular beats and nonsustained arrhythmias when antiarrhythmic drugs fail to suppress the arrhythmias. It is increasingly used in preference to antiarrhythmic drugs, sparing the patient adverse effects of drugs. Success of ablation varies with the underlying heart disease and type of arrhythmia: very effective for patients without structural heart disease, less effective in structural heart disease. Failure occurs when a target for ablation cannot be identified or ablation lesions fail to reach and abolish the arrhythmia substrate that may be extensive, intramural, or subepicardial in location. Approaches to improving ablation lesion creation are modifications to RF ablation and emerging investigational techniques. Easily- implemented modifications to RF methods include manipulating the size and location of the cutaneous dispersive electrode, increasing duration of RF delivery, and use of lower-tonicity catheter irrigation (usually 0.45% saline). When catheters can be placed on either side of culprit substrate, RF can be delivered in a bipolar or simultaneous unipolar configuration that can be successful. Catheters with extendable and retractable irrigated needles for delivery of RF are under investigation in clinical trials. Cryoablation is potentially useful with specific situations in which maintaining contact is difficult. Transvascular ethanol ablation and stereotactic radioablation have both shown promise for arrhythmias that fail other ablation strategies. Although substantial clinical progress has been achieved, further improvement is clearly needed. With ability to increase ablation lesion size, continued careful evaluation of safety, which has been excellent for standard RF ablation, remains important.

Langue d'origineEnglish
Pages (de-à)502-514
Nombre de pages13
JournalCanadian Journal of Cardiology
Volume38
Numéro de publication4
DOI
Statut de publicationPublished - avr. 2022
Publié à l'externeOui

Note bibliographique

Funding Information:
Dr Stevenson has received speaking honoraria from Abbott Medical; Boston Scientific, Inc.; Johnson and Johnson; Biotronik; and Medtronic, Inc; and consulting fees from Abiomed. He has received research funding from Thermedical. Dr Sapp has received research grants and honoraria from Biosense Webster and Abbott Medical, Inc. and honoraria from Medtronic, Inc. Dr Stevenson is co-holder of US patent #7207989 “Method for Ablating With Needle Electrode” patent for irrigated needle ablation that is consigned to Brigham Hospital. To date, no royalties have been received. Dr Sapp is co-holder of US patent #7207989 “Method for Ablating With Needle Electrode” patent for irrigated needle ablation that is consigned to Brigham Hospital. To date, no royalties have been received.

Publisher Copyright:
© 2021 Canadian Cardiovascular Society

ASJC Scopus Subject Areas

  • Cardiology and Cardiovascular Medicine

PubMed: MeSH publication types

  • Journal Article
  • Review
  • Research Support, Non-U.S. Gov't

Empreinte numérique

Plonger dans les sujets de recherche 'Newer Methods for Ventricular Tachycardia Ablation and When to Use Them'. Ensemble, ils forment une empreinte numérique unique.

Citer